絞り込み

16546

広告

Phase II Clinical Trial of First-line Eribulin Plus Trastuzumab for Advanced or Recurrent HER2-positive Breast Cancer.

著者 Sakaguchi K , Nakatsukasa K , Koyama H , Kato M , Sakuyama A , Matsuda T , Tsunoda N , Fujiwara I , Yamaguchi M , Tanaka H , Onishi K , Onishi M , Yoshino Y , Kikuchi T , Taguchi T
Anticancer Res.2018 Jul ; 38(7):4073-4081.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (39view , 0users)

Full Text Sources

Medical

Miscellaneous

Eribulin mesylate has been approved for advanced or metastatic breast cancers subjected to at least two previous chemotherapy regimens. The present multicenter, phase II, single-arm study assessed the efficacy and safety of a first-line regimen of eribulin plus trastuzumab for untreated advanced or metastatic HER2-positive breast cancer.
PMID: 29970533 [PubMed - in process]
印刷用ページを開く Endnote用テキストダウンロード